Loading
Latest filing published 20 Jan 2023 for Clearside Biomedical, Inc., €19k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Thomas Ciulla on record concern Clearside Biomedical, Inc., in the capacity of senior executive. The record holds 9 filings, for trades running from 18 January 2021 to 20 January 2023.
No open-market purchase appears, only 4 sales worth €53k. The rest of the record consists of 5 share grants. So far in 2023, the count stands at no purchases and 2 sales.
The newest entry dates from 20 January 2023: an open-market sale of €19k, in Clearside Biomedical, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations